AI Article Synopsis
- The study explores the connection between the apolipoprotein B/A1 ratio, apolipoprotein B, and apolipoprotein A1 levels and the metabolic syndrome (MetS) in children and adolescents.
- It analyzed data from 5 studies involving 232 participants with MetS and 1320 controls, finding high levels of apolipoprotein B/A1 and B, and low levels of apolipoprotein A1 associated with MetS.
- The authors emphasize the importance of monitoring apolipoprotein levels to help identify MetS risk in younger populations.
Article Abstract
Objectives: Metabolic syndrome (MetS) is a constellation of coexisting cardiovascular risk factors. This study aimed to assess the evidence for the association between the apolipoprotein B/A1 ratio, apolipoprotein B, and apolipoprotein A1, and the MetS in children and adolescents.
Methods: The English electronic databases including PubMed, Embase, Web of Science, and Scopus were searched up to February 28, 2022. To ascertain the validity of eligible studies, modified JBI scale was used. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using the random-effects model to evaluate the association between the apolipoprotein B/A1 ratio, apolipoprotein B, and apolipoprotein A1 and the MetS. Heterogeneity amongst the studies was determined by the use of the Galbraith diagram, Cochran's Q-test, and I test. Publication bias was assessed using Egger's and Begg's tests.
Results: From 7356 records, 5 studies were included in the meta-analysis, representing a total number of 232 participants with MetS and 1320 participants as control group. The results indicated that increased levels of apolipoprotein B/A1 ratio (SMD 1.26; 95% CI: 1.04, 1.47) and apolipoprotein B (SMD 0.75; 95% CI: 0.36, 1.14) and decreased levels of apolipoprotein A1 (SMD -0.53; 95% CI: -0.69, -0.37) are linked to the presence of MetS. The notable findings were, children and adolescents with MetS had elevated levels of the apolipoprotein B/A1 ratio, apolipoprotein B, and decreased levels of apolipoprotein A1.
Conclusions: Our results suggest the need to evaluate the levels of apolipoproteins for detecting the risk of MetS in children and adolescents.
Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-023-01235-z.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196517 | PMC |
| http://dx.doi.org/10.1007/s40200-023-01235-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.
BMC Cancer
December 2024
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Background: Dyslipidemia is a common comorbidity in patients with cancer, yet the impact of abnormal lipid levels on tumor prognosis remains contentious. This study was conducted to synthesize the current evidence regarding the prognostic utility of blood lipid levels, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB), in predicting overall survival (OS) and disease-free survival (DFS) in cancer patients.
Methods: A comprehensive literature search was performed across electronic databases to assess the associations between blood lipid levels and OS or DFS in cancer patients.
Metabonomic Biomarkers of Plaque Burden and Instability in Patients With Coronary Atherosclerotic Disease After Moderate Lipid-Lowering Therapy.
J Am Heart Assoc
December 2024
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases National Clinical Research Center for Interventional Medicine Shanghai China.
Background: Contemporary risk assessment in patients with coronary atherosclerotic disease (CAD) often relies on invasive angiography. However, we aimed to explore the potential of metabolomic biomarkers in reflecting residual risk in patients with CAD after moderate lipid-lowering therapy.
Methods And Results: We analyzed serum metabolomic profile among 2560 patients with newly diagnosed CAD undergoing moderate lipid-lowering therapy, through nuclear magnetic resonance spectroscopy and quantified 175 metabolites, predominantly lipoproteins and their components.
Longitudinal analysis of adiponectin to leptin and apolipoprotein B to A1 ratios as markers of future airflow obstruction and lung function decline.
Sci Rep
November 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 56, Dongsu-ro, Bupyeong-gu, Incheon, 21431, Republic of Korea.
Previous studies suggest associations between the risk of developing chronic obstructive pulmonary disease (COPD) and adiponectin/leptin (ALR) and apolipoprotein B/A1 (APOR) ratios. This longitudinal observational study, using data from the Korean Genome and Epidemiology Study (KoGES), examined the rate of lung function decline, risk factors for the airflow obstruction (AFO), and the time to first AFO based on ALR and APOR groups. Among 5578 participants, high ALR and low APOR were associated with rapid decline in lung function and a shorter time to the first AFO.
View Article and Find Full Text PDFApolipoprotein B/Apolipoprotein A1 ratio is an independent prognostic factor in pancreatic cancer.
Transl Oncol
January 2025
Department of Cardiology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, PR China. Electronic address:
Article Synopsis
- The study aimed to explore how serum lipid levels relate to the prognosis of pancreatic cancer in patients.
- Researchers analyzed data from 286 patients over four years and assessed factors like clinical characteristics and survival rates.
- They found that high levels of apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) are linked to shorter overall and progression-free survival, suggesting it could be an important prognostic factor for pancreatic cancer.
Association analyses of nutritional markers with Parkinson's disease and Alzheimer's disease.
Heliyon
November 2024
Department of Neurology, Institute of Geriatric Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Article Synopsis
- - The study investigates the relationship between nutritional markers and the risk of Parkinson's disease (PD) and Alzheimer's disease (AD) among 424 PD patients, 314 AD patients, and 388 healthy controls.
- - Key findings reveal that higher levels of apolipoprotein B (ApoB), low-density lipoprotein (LDL), and total cholesterol (TC) are linked to a lower risk of PD, while homocysteine (HCY) levels increase the risk; for AD, ApoA1 shows protective effects, while HCY acts as a risk factor.
- - The results highlight the significance of lipid and one-carbon metabolism in the development of PD and AD, emphasizing the nutritional aspects that could influence these
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!